Eli Lilly and Company LLY
Eli Lilly and Company (NYSE: LLY) is a cardio-renal-metabolic drug developer. Its lead program, retatrutide, is in Phase 3 for obesity and type 2 diabetes.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| insulin efsitora alfa (Onswik) | type 2 diabetes | protein/peptide | Approved |
| orforglipron (Foundayo) | obesity and type 2 diabetes | small molecule | Approved |
| tirzepatide (Mounjaro) | cardiovascular risk reduction in type 2 diabetes | protein/peptide | Approved |
| tirzepatide (Zepbound) | obesity | protein/peptide | Approved |
| retatrutide | obesity | protein/peptide | Phase 3 |
| retatrutide | type 2 diabetes | protein/peptide | Phase 3 |
| baricitinib | type 1 diabetes | small molecule | Phase 3 |
| eloralintide | obesity (incretin add-on) | protein/peptide | Phase 3 |
| eloralintide | obstructive sleep apnea | protein/peptide | Phase 3 |
| eloralintide | osteoarthritis pain | protein/peptide | Phase 3 |
| brenipatide | major depressive disorder | protein/peptide | Phase 3 |
| sofetabart mipitecan | platinum-sensitive ovarian cancer | small molecule | Phase 3 |
| tersolisib | PIK3CA+ advanced breast cancer | small molecule | Phase 3 |
Recent results and decisions
- Oct 29, 2026approval FDA approves Mounjaro to reduce cardiovascular risk in adults with type 2 diabetes.
FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
Filing - Oct 29, 2026approval FDA approves Onswik, a once-weekly basal insulin for adults with type 2 diabetes.
U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes
Filing - Oct 29, 2026approval FDA approves Inluriyo with Verzenio for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer.
U.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
Filing
6 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.